A mass on the heart is any abnormal growth or collection of material found inside the heart chambers, within the heart muscle, or on the surfaces of the heart’s valves. These masses range from benign tumors like myxomas, to aggressive cancers like angiosarcomas, to non-tumor formations like blood clots and valve vegetations. Most are rare, and the vast majority that doctors encounter today are found incidentally during imaging for something else entirely.
Why Cardiac Masses Are Found More Often Now
For most of medical history, cardiac tumors were diagnosed at autopsy. The widespread use of echocardiography, cardiac MRI, and CT scanning has changed that picture dramatically, and masses that would have gone undetected a generation ago now show up on routine scans ordered for chest pain, irregular heartbeats, or pre-surgical workups.1Structural Heart. Cardiac Masses Discovered by Echocardiogram; What to Do Next? That shift matters because finding a mass early often means more treatment options and a better outcome, particularly for tumors that can throw off fragments into the bloodstream.
When a mass is detected, the first clinical question is always the same: is this a true tumor, or is it something else mimicking one? Blood clots lodged in the heart, infectious growths on valves, and even normal anatomic variants can all look like tumors on a quick ultrasound. Sorting out what the mass actually is determines everything that follows.
Myxomas, the Most Common Primary Cardiac Tumor
Among true tumors that originate in the heart itself, myxomas are by far the most frequent in adults. They are benign, meaning they do not invade surrounding tissue or spread to distant organs the way cancer does. Most arise in the left atrium, typically hanging from a stalk attached to the inner wall of the chamber.2US Cardiology Review. Giant Left Atrial Myxoma Presenting with Severe Pulmonary Hypertension Their position near the mitral valve is what causes trouble: as the mass swings with each heartbeat, it can partially block blood flow through the valve or shed fragments that travel to the brain or other organs.
A classic presentation involves three categories of symptoms. About two-thirds of patients experience signs of valve obstruction, mainly heart failure symptoms like breathlessness and fatigue. Roughly a third develop problems from embolism, most often a stroke caused by a fragment reaching the brain. And about a third show constitutional symptoms such as fever, weight loss, or joint pain that can mimic autoimmune disease, driven by inflammatory signaling molecules the tumor releases.3PubMed. Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases That last group of symptoms is particularly tricky because patients may go through extensive rheumatologic workups before anyone thinks to image the heart.
A substantial number of myxomas, however, produce no symptoms at all and are caught purely by chance. One large surgical series found that about one in six patients with confirmed atrial myxoma had been completely asymptomatic, with dyspnea being the most common complaint in those who did have symptoms.4European Heart Journal Supplements. Long-term outcomes after surgical resection of atrial myxoma: a 13-year experience at a tertiary referral centre
Cardiac Tumors in Children
The tumor landscape looks entirely different in fetuses, newborns, and young children. In that age group, rhabdomyomas are the most common cardiac tumor. These are benign growths made of abnormal heart muscle cells, and they are tightly linked to tuberous sclerosis complex, a genetic condition that causes noncancerous growths in multiple organs. Most rhabdomyomas are detected either before birth on a fetal ultrasound or shortly after delivery, and multiple tumors are the norm rather than the exception.5PubMed Central. Cardiac rhabdomyomas in tuberous sclerosis complex: clinical manifestations and genotype correlations
The encouraging aspect of rhabdomyomas is that they tend to shrink on their own during early childhood. The tumor cells appear to undergo accelerated cell death, which drives a gradual regression that can lead to complete or near-complete disappearance without any treatment.6PubMed. Study of the regression process in cardiac rhabdomyomas For that reason, asymptomatic rhabdomyomas are generally watched rather than operated on. The exception is when a tumor causes severe obstruction of blood flow or dangerous heart rhythm disturbances, which can require emergency intervention.7PubMed Central. Spontaneous Regression of Cardiac Rhabdomyoma Presenting as Severe Left Ventricular Inlet Obstruction in a Neonate with Tuberous Sclerosis
Fibromas are the other major pediatric cardiac tumor. Unlike rhabdomyomas, fibromas do not shrink on their own and typically need to be surgically removed.8PubMed. Pediatric cardiac tumors: clinical and imaging features The distinction between these two tumors is one reason careful imaging matters so much in children with heart masses.
Malignant Primary Cardiac Tumors
Cancers that start in the heart are genuinely rare, but when they occur, they tend to be aggressive. Angiosarcoma is the most common malignant primary cardiac tumor. It usually arises in the right atrium and has a tendency to metastasize early and widely.9PubMed Central. Primary cardiac tumor: a case report of right atrial angiosarcoma and review of the literature Prognosis remains poor despite advances in treatment, and management centers on a combination of surgical removal, chemotherapy, and sometimes radiation.10PubMed Central. Multidisciplinary Management of a Rare Primary Cardiac Angiosarcoma
A two-decade review of primary cardiac sarcomas at one major center found that about three-quarters of patients underwent surgical resection and a similar proportion received systemic chemotherapy, with roughly one in five also getting radiation. That kind of multimodal approach is now standard because no single therapy has proven sufficient on its own.11PubMed Central. Primary cardiac sarcoma: insights from two decades of multimodal management at LMU Munich
Primary cardiac lymphoma is another rare malignancy, most often a diffuse large B-cell type. It preferentially involves the right side of the heart and is more common in people with compromised immune systems.12PubMed Central. Primary cardiac lymphoma: a case report and review of literature Symptoms tend to be vague and nonspecific, which means the diagnosis is often delayed. Location within the heart matters: when the left ventricle is involved, outcomes are significantly worse compared to tumors confined to the right side.13PubMed. Primary cardiac lymphoma: an analysis of presentation, treatment, and outcome patterns
When Cancer Spreads to the Heart From Elsewhere
Metastatic tumors in the heart, where cancer from another organ seeds into cardiac tissue, are actually far more common than primary cardiac malignancies. No specific cancer type preferentially targets the heart, but some are found there more often than others. Melanoma and cancers originating in the chest, such as lung cancer and mediastinal tumors, are particularly frequent sources of cardiac metastases.14PubMed Central. Cardiac metastases These secondary deposits can involve any chamber or the pericardium and may cause symptoms ranging from fluid buildup around the heart to obstruction of blood flow, depending on their size and location.
Treatment of metastatic cardiac masses is generally governed by the treatment of the underlying cancer. If the primary malignancy responds to chemotherapy or immunotherapy, the cardiac lesions often respond as well. Surgery on cardiac metastases is uncommon and typically reserved for situations where the mass threatens to cause acute, life-threatening obstruction.
Non-Tumor Masses That Mimic Cardiac Tumors
Not every mass in the heart is a tumor. In adults, the single most common type of cardiac mass is actually a blood clot, or thrombus. Thrombi form in the heart for different reasons depending on location. In the left atrial appendage, a small pouch off the left atrium, clots develop because of sluggish blood flow, and the risk skyrockets in people with atrial fibrillation. The irregular heart rhythm promotes a local environment where blood stagnates and clotting factors become concentrated, creating ideal conditions for thrombus formation.15PubMed Central. The Left Atrial Appendage and Atrial Fibrillation-A Contemporary Review 16PubMed. Coagulation factors and fibrinolytic activity in the left atrial appendage and other heart chambers in patients with atrial fibrillation: is there a local intracardiac prothrombotic state? (HEART-CLOT study) These clots can break free and travel to the brain, causing a stroke, which is why anticoagulation is such a central part of managing atrial fibrillation.17PubMed. Modelling of thrombus formation, growth and embolisation in the left atrial appendage under atrial fibrillation
Vegetations are another non-tumor mass. These are clumps of bacteria, immune cells, and clotting material that form on heart valves during infective endocarditis. But vegetations can also be sterile, forming in conditions called non-bacterial thrombotic endocarditis. Sterile vegetations tend to develop in people with advanced cancer or autoimmune diseases, and they typically sit on the mitral or aortic valves.18IntechOpen. Non-bacterial Thrombotic Endocarditis They are often more fragile than their infectious counterparts, which paradoxically makes them more likely to throw off fragments and cause strokes or organ damage.19PubMed Central. Overview and Comparison of Infectious Endocarditis and Non-infectious Endocarditis: A Review of 814 Autoptic Cases
How Cardiac Masses Are Diagnosed
The workhorse tool is echocardiography. A standard transthoracic echocardiogram (the kind done through the chest wall) can detect many cardiac masses, but it misses a fair number. One large study comparing imaging modalities found that standard echocardiography correctly identified the mass in about 69% of cases. Transesophageal echocardiography, where the probe is passed into the esophagus for a closer view, pushed accuracy to about 97%.20PubMed. Use of transesophageal echocardiography and contrast echocardiography in the evaluation of cardiac masses Contrast echocardiography, which involves injecting a microbubble agent into the bloodstream, performed similarly well and can help distinguish tumor tissue from clot without exposing the patient to radiation.
Cardiac MRI is the gold standard for characterizing what a mass actually is once it has been found. Different MRI sequences can distinguish between tumor and clot with high reliability, though accuracy drops for masses smaller than about one centimeter.21Journal of Cardiovascular Magnetic Resonance. The accuracy of cardiac MRI in differentiating between intra cardiac tumors and thrombi For masses suspected to be cancerous, PET/CT scanning adds another layer by measuring how actively the tissue is consuming glucose, which helps differentiate benign tumors from malignant ones and can reveal whether cancer has spread elsewhere in the body.22Cancer Treatment and Research Communications. Scope of PET imaging in the evaluation of cardiac tumors
In ambiguous cases where imaging alone cannot settle the diagnosis, a percutaneous transcatheter biopsy may be performed. A catheter is threaded through a blood vessel into the heart, and small tissue samples are snipped from the mass. This is not a trivial procedure: one review found that about 7% of patients developed ventricular arrhythmias requiring immediate cardioversion during the biopsy. However, the technique yielded a tissue diagnosis in about 72% of cases and changed the treatment plan in over half.23EuroIntervention. Percutaneous transcatheter biopsy for intracardiac mass diagnosis Biopsying masses on the left side of the heart carries an added risk of tumor fragments embolizing to the brain, a complication that has led some teams to deploy cerebral protection devices during the procedure.24JACC: Case Reports. Cerebral Embolic Protection During Transseptal Biopsy of Left Atrial Mass
Surgery for Benign Cardiac Tumors
For myxomas, surgical excision is the definitive treatment and is recommended promptly once the diagnosis is established, because the risk of stroke from tumor embolization hangs over every day the mass remains in place. The operation involves open-heart surgery with the patient on a heart-lung bypass machine. The tumor and its base of attachment are removed, often with a margin of surrounding tissue to reduce the chance of recurrence.
Outcomes are excellent. A worldwide meta-analysis reported early surgical mortality of about 1.3%.25PubMed. Clinical characteristics and surgical outcomes of cardiac myxoma: A meta-analysis of worldwide experience One single-center series of 84 patients had zero in-hospital deaths, with survival rates of about 98% at one year and 89% at five years, figures comparable to the general population of the same age.4European Heart Journal Supplements. Long-term outcomes after surgical resection of atrial myxoma: a 13-year experience at a tertiary referral centre A larger study of over 400 cases found early mortality of 0.7%, with tumor recurrence occurring in six patients and new-onset atrial fibrillation developing in about 12% during follow-up.26PubMed Central. Long-term outcome of patients with atrial myxoma after surgical intervention: analysis of 403 cases
Treatment for Blood Clots and Malignant Tumors
Cardiac thrombi are treated with blood thinners rather than surgery. Traditionally, warfarin has been the standard anticoagulant for dissolving left ventricular clots, but newer direct oral anticoagulants have gained traction. A meta-analysis of 31 studies found that direct oral anticoagulants performed at least as well as warfarin at resolving thrombi, while producing a statistically significant reduction in stroke risk, all-cause mortality, and bleeding events compared to warfarin.27PubMed Central. Meta-Analysis of the Safety and Efficacy of Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombus That finding is shifting clinical practice toward these newer drugs for many patients.
For malignant primary cardiac tumors, treatment depends on the specific cancer type. Cardiac sarcomas are primarily treated with surgery combined with chemotherapy, and sometimes radiation. The surgery itself can be technically demanding because these tumors often grow into surrounding structures or involve the great vessels. Complete surgical removal, when achievable, remains the strongest predictor of better outcomes, but margins are often difficult to clear in such a confined and vital space. Primary cardiac lymphoma, by contrast, typically responds to chemotherapy regimens used for lymphomas elsewhere in the body, and surgery plays a smaller role.
Recurrence and Long-Term Monitoring
Even after successful removal, myxomas can come back. Recurrence is uncommon overall, but the risk is real and varies significantly based on context. In familial cases linked to genetic syndromes, recurrence runs around 2-3%, while sporadic (non-hereditary) cases recur less often.28PubMed Central. Recurrent Left Atrial Myxoma: The Significance of Active Surveillance Most recurrences appear within the first three to four years after surgery.29PubMed. Survival after resection of primary cardiac tumors: a 48-year experience
That timeline has led most centers to recommend annual echocardiograms for at least several years after surgery. But the surveillance question is not fully settled. One case report documented a recurrence seven years after initial removal in a patient who was completely asymptomatic and whose tumor was caught only because of ongoing annual surveillance.28PubMed Central. Recurrent Left Atrial Myxoma: The Significance of Active Surveillance A long-term follow-up study documented even more dramatic cases, including one patient who required repeat operations over a span of nearly two decades as myxomas kept reappearing in different heart chambers.30PubMed Central. Clinical characteristics and long term post-operative outcome of cardiac myxoma These outlier cases raise the question of whether surveillance should extend well beyond the usual three-to-four-year window, particularly in younger patients.
Overall long-term survival after myxoma removal is good. One study with a mean follow-up of about seven years reported five-year survival of about 98% and fifteen-year survival of roughly 90%.30PubMed Central. Clinical characteristics and long term post-operative outcome of cardiac myxoma
The Carney Complex Connection
Most cardiac myxomas occur sporadically with no clear genetic cause. But a small subset are linked to Carney complex, an inherited condition that causes tumors in multiple organs including the heart, skin, and endocrine glands. Carney complex follows an autosomal dominant inheritance pattern, meaning a child of an affected parent has a 50% chance of inheriting it.31PubMed. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex
About 80% of Carney complex patients who undergo genetic testing carry mutations in a gene called PRKAR1A, which codes for a component of a key cellular signaling pathway.32PubMed Central. Detection of PRKAR1A gene mutations in sporadic cardiac myxomas: a study of 24 cases Patients with Carney complex tend to develop myxomas at a younger age and in multiple cardiac chambers, and their recurrence risk after surgery is higher than the average patient’s. When a young person presents with a cardiac myxoma, especially if they have skin pigmentation abnormalities or tumors in other organs, genetic evaluation for Carney complex is warranted because it changes the surveillance plan for both the patient and their family members.
Recent research has also looked at whether sporadic myxomas, those without any family history, carry mutations in the same gene. That work is still evolving, but it suggests that at least some “sporadic” cases may have acquired mutations in the same pathway, blurring the line between hereditary and non-hereditary forms of the disease.
When the Mass Turns Out to Be Nothing
One scenario that does not get enough attention: sometimes a “cardiac mass” on imaging is not really an abnormal structure at all. Normal anatomic features inside the heart, such as the moderator band in the right ventricle, the Chiari network (a thin membrane in the right atrium), or a prominent Eustachian valve, can all be mistaken for pathologic masses on echocardiography, especially by less experienced operators. Lipomatous hypertrophy of the atrial septum, where fat deposits thicken the wall between the two atria, is another common mimic that is entirely benign and requires no treatment.
This is partly why the progression from basic echocardiography to more advanced imaging like cardiac MRI exists. When a mass is found incidentally and the patient is otherwise well, the measured approach is usually to get better imaging and characterize the mass before jumping to biopsy or surgery. The stakes of misidentifying a harmless variant as a tumor and proceeding to open-heart surgery are obvious, and the stakes of dismissing a real tumor as a normal variant are equally serious. Getting that distinction right is the central diagnostic challenge of cardiac masses.